{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T15:05:14Z","timestamp":1790867114855,"version":"4.1.0"},"reference-count":39,"publisher":"Centers for Disease Control and Prevention (CDC)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Emerg. Infect. Dis."],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.3201\/eid2809.220458","type":"journal-article","created":{"date-parts":[[2022,8,22]],"date-time":"2022-08-22T08:16:54Z","timestamp":1661156214000},"page":"1796-1804","source":"Crossref","is-referenced-by-count":16,"title":["Revised Definitions of Tuberculosis Resistance and Treatment Outcomes, France, 2006\u20132019"],"prefix":"10.3201","volume":"28","author":[{"given":"Yousra","family":"Kherabi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathilde","family":"Fr\u00e9chet-Jachym","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Rioux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yazdan","family":"Yazdanpanah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"M\u00e9cha\u00ef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Pourcher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Robert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Guglielmetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the MDR-TB Management Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1822","reference":[{"key":"key-10.3201\/eid2809.220458-202208171141-R1","unstructured":"World Health Organization. Global tuberculosis report 2021. 2021 [cited 2021 Nov 7]. https:\/\/www.who.int\/teams\/global-tuberculosis-programme\/tb-reports\/global-tuberculosis-report-2021"},{"key":"key-10.3201\/eid2809.220458-202208171141-R2","doi-asserted-by":"publisher","first-page":"20555","DOI":"10.2807\/1560-7917.ES2013.18.33.20555","article-title":"A surge of MDR and XDR tuberculosis in France among patients born in the Former Soviet Union.","volume":"18","author":"Bernard","year":"2013","journal-title":"Euro Surveill"},{"key":"key-10.3201\/eid2809.220458-202208171141-R3","first-page":"1","article-title":"EMC","volume":"1","author":"Guthmann","year":"2019","journal-title":"Pneumologie"},{"key":"key-10.3201\/eid2809.220458-202208171141-R4","unstructured":"Tuberculosis in France: epidemiological data 2019 [in French]. 2021 [cited 2021 Oct 15]. https:\/\/www.santepubliquefrance.fr\/les-actualites\/2021\/tuberculose-en-france-donnees-epidemiologiques-2019"},{"key":"key-10.3201\/eid2809.220458-202208171141-R5","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/S0140-6736(18)31644-1","article-title":"Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis.","volume":"392","author":"Ahmad","year":"2018","journal-title":"Lancet"},{"key":"key-10.3201\/eid2809.220458-202208171141-R6","unstructured":"World Health Organization. WHO consolidated guidelines on drug-resistant tuberculosis treatment. Licence: CC BY-NC-SA 3.0 IGO. Geneva: The Organization. 2019."},{"key":"key-10.3201\/eid2809.220458-202208171141-R7","unstructured":"World Health Organization. Meeting report of the WHO expert consultation on the definition of extensively drug-resistant tuberculosis [cited 2021 May 17]. https:\/\/www.who.int\/publications-detail-redirect\/meeting-report-of-the-who-expert-consultation-on-the-definition-of-extensively-drug-resistant-tuberculosis"},{"key":"key-10.3201\/eid2809.220458-202208171141-R8","doi-asserted-by":"publisher","first-page":"e1001300","DOI":"10.1371\/journal.pmed.1001300","article-title":"Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients.","volume":"9","author":"Ahuja","year":"2012","journal-title":"PLoS Med"},{"key":"key-10.3201\/eid2809.220458-202208171141-R9","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1164\/rccm.202009-3527OC","article-title":"Evidence-based definition for extensively drug-resistant tuberculosis.","volume":"204","author":"Roelens","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"key-10.3201\/eid2809.220458-202208171141-R10","doi-asserted-by":"publisher","first-page":"395","DOI":"10.5588\/ijtld.21.0036","article-title":"Therapeutic strategies and outcomes of MDR and pre-XDR-TB in Italy: a nationwide study.","volume":"25","author":"Riccardi","year":"2021","journal-title":"Int J Tuberc Lung Dis"},{"key":"key-10.3201\/eid2809.220458-202208171141-R11","doi-asserted-by":"crossref","unstructured":"Lee EH, Yong SH, Leem AY, Lee SH, Kim SY, Chung KS,  Improved fluoroquinolone-resistant and extensively drug-resistant tuberculosis treatment outcomes. Open Forum Infect Dis. 2019;6:ofz118. 10.1093\/ofid\/ofz118","DOI":"10.1093\/ofid\/ofz118"},{"key":"key-10.3201\/eid2809.220458-202208171141-R12","unstructured":"World Health Organization. Policy guidance on drug-susceptibility testing (DST) of second-line antituberculosis drugs. 2008 [cited 2020 Aug 4]. https:\/\/apps.who.int\/iris\/handle\/10665\/70500"},{"key":"key-10.3201\/eid2809.220458-202208171141-R13","unstructured":"World Health Organization. Meeting report of the WHO expert consultation on drug-resistant tuberculosis treatment outcome definitions; Geneva, Switzerland; November 17\u201319, 2020 [cited 2021 Oct 15]. https:\/\/www.who.int\/publications-detail-redirect\/9789240022195"},{"key":"key-10.3201\/eid2809.220458-202208171141-R14","unstructured":"World Health Organization. Consolidated guidelines on tuberculosis. Module 4: treatment\u2014drug-resistant tuberculosis treatment [cited 2021 Nov 7]. https:\/\/www.who.int\/publications-detail-redirect\/9789240007048"},{"key":"key-10.3201\/eid2809.220458-202208171141-R15","unstructured":"High Council for Public Hygiene. Tuberculosis with resistant bacilli: diagnosis and management. HCSP report [in French]. 2014 Dec [cited 2020 Aug 2]. https:\/\/www.hcsp.fr\/explore.cgi\/avisrapportsdomaine?clefr=483"},{"key":"key-10.3201\/eid2809.220458-202208171141-R16","doi-asserted-by":"crossref","unstructured":"Guglielmetti L, Jaffr\u00e9 J, Bernard C, Brossier F, El Helali N, Chadelat K,  Multidisciplinary advisory teams to manage multidrug-resistant tuberculosis: the example of the French Consilium. Int J Tuberc Lung Dis. 2019;23:1050\u20134.","DOI":"10.5588\/ijtld.18.0779"},{"key":"key-10.3201\/eid2809.220458-202208171141-R17","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.rppnen.2017.10.005","article-title":"Team approach to manage difficult-to-treat TB cases: Experiences in Europe and beyond.","volume":"24","author":"D\u2019Ambrosio","year":"2018","journal-title":"Pulmonology"},{"key":"key-10.3201\/eid2809.220458-202208171141-R18","unstructured":"US Food and Drug Administration. What is a serious adverse event? 2020 Sep 9 [cited 2021 Oct 15]. https:\/\/www.fda.gov\/safety\/reporting-serious-problems-fda\/what-serious-adverse-event"},{"key":"key-10.3201\/eid2809.220458-202208171141-R19","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1086\/522537","article-title":"Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrug-resistant tuberculosis.","volume":"45","author":"Kim","year":"2007","journal-title":"Clin Infect Dis"},{"key":"key-10.3201\/eid2809.220458-202208171141-R20","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1164\/rccm.200801-132OC","article-title":"Treatment outcomes and long-term survival in patients with extensively drug-resistant tuberculosis.","volume":"178","author":"Kim","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"key-10.3201\/eid2809.220458-202208171141-R21","doi-asserted-by":"publisher","first-page":"525","DOI":"10.5588\/ijtld.14.0739","article-title":"Changes in treatment outcomes of multidrug-resistant tuberculosis.","volume":"19","author":"Kwak","year":"2015","journal-title":"Int J Tuberc Lung Dis"},{"key":"key-10.3201\/eid2809.220458-202208171141-R22","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1183\/09031936.00134712","article-title":"Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes.","volume":"42","author":"Falzon","year":"2013","journal-title":"Eur Respir J"},{"key":"key-10.3201\/eid2809.220458-202208171141-R23","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1056\/NEJMoa1313865","article-title":"Multidrug-resistant tuberculosis and culture conversion with bedaquiline.","volume":"371","author":"Diacon","year":"2014","journal-title":"N Engl J Med"},{"key":"key-10.3201\/eid2809.220458-202208171141-R24","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1183\/09031936.00125812","article-title":"Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis.","volume":"41","author":"Skripconoka","year":"2013","journal-title":"Eur Respir J"},{"key":"key-10.3201\/eid2809.220458-202208171141-R25","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1164\/rccm.201801-0019LE","article-title":"Bedaquiline and repurposed drugs for fluoroquinolone-resistant multidrug-resistant tuberculosis: how much better are they?","volume":"198","author":"Bastard","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"key-10.3201\/eid2809.220458-202208171141-R26","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1056\/NEJMoa1201964","article-title":"Linezolid for treatment of chronic extensively drug-resistant tuberculosis.","volume":"367","author":"Lee","year":"2012","journal-title":"N Engl J Med"},{"key":"key-10.3201\/eid2809.220458-202208171141-R27","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1056\/NEJMc1500286","article-title":"Linezolid for XDR-TB\u2014final study outcomes.","volume":"373","author":"Lee","year":"2015","journal-title":"N Engl J Med"},{"key":"key-10.3201\/eid2809.220458-202208171141-R28","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1183\/09031936.00035114","article-title":"Efficacy, safety and tolerability of linezolid for the treatment of XDR-TB: a study in China.","volume":"45","author":"Tang","year":"2015","journal-title":"Eur Respir J"},{"key":"key-10.3201\/eid2809.220458-202208171141-R29","doi-asserted-by":"crossref","unstructured":"Dooley KE, Sayre P, Borland J, Purdy E, Chen S, Song I,  Safety, tolerability, and pharmacokinetics of the HIV integrase inhibitor dolutegravir given twice daily with rifampin or once daily with rifabutin: results of a phase 1 study among healthy subjects. J Acquir Immune Defic Syndr 2013;62:21\u20137.","DOI":"10.1097\/QAI.0b013e318276cda9"},{"key":"key-10.3201\/eid2809.220458-202208171141-R30","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1183\/13993003.00411-2016","article-title":"Is bedaquiline as effective as fluoroquinolones in the treatment of multidrug-resistant tuberculosis?","volume":"48","author":"Guglielmetti","year":"2016","journal-title":"Eur Respir J"},{"key":"key-10.3201\/eid2809.220458-202208171141-R31","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1056\/NEJMoa1901814","article-title":"Treatment of highly drug-resistant pulmonary tuberculosis.","volume":"382","author":"Conradie","year":"2020","journal-title":"N Engl J Med"},{"key":"key-10.3201\/eid2809.220458-202208171141-R32","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1056\/NEJMoa1811867","article-title":"A trial of a shorter regimen for rifampin-resistant tuberculosis.","volume":"380","author":"Nunn","year":"2019","journal-title":"N Engl J Med"},{"key":"key-10.3201\/eid2809.220458-202208171141-R33","doi-asserted-by":"publisher","first-page":"e0000313","DOI":"10.1371\/journal.pgph.0000313","article-title":"Patient-centered approach to the management of drug-resistant tuberculosis in France: How far off the mark are we?","volume":"2","author":"Kherabi","year":"2022","journal-title":"PLOS Glob Public Health."},{"key":"key-10.3201\/eid2809.220458-202208171141-R34","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.5588\/ijtld.11.0811","article-title":"Predictors of sputum culture conversion among patients treated for multidrug-resistant tuberculosis.","volume":"16","author":"Kurbatova","year":"2012","journal-title":"Int J Tuberc Lung Dis"},{"key":"key-10.3201\/eid2809.220458-202208171141-R35","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.5588\/ijtld.18.0649","article-title":"What is the best culture conversion prognostic marker for patients treated for multidrug-resistant tuberculosis?","volume":"23","author":"Bastard","year":"2019","journal-title":"Int J Tuberc Lung Dis"},{"key":"key-10.3201\/eid2809.220458-202208171141-R36","unstructured":"Veziris N, Bonnet I, Morel F, Guglielmetti L, Maitre T, Ray LFL,  Impact of the revised definition of extensively drug resistant tuberculosis. Eur Respir J. 2021 Jan 1 [cited 2021 Nov 1]. https:\/\/erj.ersjournals.com\/content\/early\/2021\/04\/08\/13993003.00641-2021"},{"key":"key-10.3201\/eid2809.220458-202208171141-R37","doi-asserted-by":"publisher","first-page":"e0250028","DOI":"10.1371\/journal.pone.0250028","article-title":"Evaluation of drug-resistant tuberculosis treatment outcome in Portugal, 2000-2016.","volume":"16","author":"Oliveira","year":"2021","journal-title":"PLoS One"},{"key":"key-10.3201\/eid2809.220458-202208171141-R38","doi-asserted-by":"publisher","first-page":"1702122","DOI":"10.1183\/13993003.02122-2017","article-title":"Relapse-free cure from multidrug-resistant tuberculosis in Germany.","volume":"51","author":"Heyckendorf","year":"2018","journal-title":"Eur Respir J"},{"key":"key-10.3201\/eid2809.220458-202208171141-R39","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/S2213-2600(20)30047-3","article-title":"Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis.","volume":"8","author":"Lan","year":"2020","journal-title":"Lancet Respir Med"}],"container-title":["Emerging Infectious Diseases"],"original-title":[],"link":[{"URL":"https:\/\/wwwnc.cdc.gov\/eid\/article\/28\/9\/22-0458_article","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T12:56:48Z","timestamp":1732971408000},"score":1,"resource":{"primary":{"URL":"https:\/\/wwwnc.cdc.gov\/eid\/article\/28\/9\/22-0458_article.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":39,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"URL":"https:\/\/doi.org\/10.3201\/eid2809.220458","relation":{},"ISSN":["1080-6040","1080-6059"],"issn-type":[{"value":"1080-6040","type":"print"},{"value":"1080-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9]]}}}